Morgan Stanley Maintains Equal-Weight on Ginkgo Bioworks Holdings, Lowers Price Target to $1
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Tejas Savant maintains an Equal-Weight rating on Ginkgo Bioworks Holdings (NYSE:DNA) but lowers the price target from $2 to $1.
May 15, 2024 | 2:25 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Morgan Stanley has maintained its Equal-Weight rating on Ginkgo Bioworks Holdings but has lowered the price target from $2 to $1, indicating a less optimistic outlook.
The lowered price target from $2 to $1 by Morgan Stanley suggests a less optimistic outlook for Ginkgo Bioworks Holdings, which could negatively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100